Aplastic anemia associated with osimertinib: Analysis of the FDA adverse event reporting system
Int. Journal of Clinical Pharmacology and Therapeutics · 2025
DOI: 10.5414/cp204627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2025. Verfasst von Katsuhiro Ohyama und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Aniline Compounds, Acrylamides, United States Food and Drug Administration, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Ohyama, K., Katagiri, S., Takahashi, S., Ayuhara, H., Takeuchi, H., Akahane, D., Gotoh, A., & Hori, Y. (2025). Aplastic anemia associated with osimertinib: Analysis of the FDA adverse event reporting system. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204627
Vancouver
Ohyama K, Katagiri S, Takahashi S, Ayuhara H, Takeuchi H, Akahane D, et al. Aplastic anemia associated with osimertinib: Analysis of the FDA adverse event reporting system. Int. Journal of Clinical Pharmacology and Therapeutics. 2025. doi:10.5414/cp204627
BibTeX
@article{Ohyama2025,
author = {Ohyama, Katsuhiro and Katagiri, Seiichiro and Takahashi, Satoshi and Ayuhara, Hideaki and Takeuchi, Hironori and Akahane, Daigo and Gotoh, Akihiko and Hori, Yusuke},
title = {Aplastic anemia associated with osimertinib: Analysis of the FDA adverse event reporting system},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2025},
doi = {10.5414/cp204627}
}
EUVIMED